Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04191499
Title	A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer (INAVO120)
Acronym	INAVO120
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Hoffmann-La Roche
Indications	Her2-receptor negative breast cancer
Therapies	Fulvestrant + Palbociclib Fulvestrant + Inavolisib + Palbociclib
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| POL \| NZL \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| BRA \| BEL \| AUS \| ARG